Eikonizo Therapeutics Enter Agreement to Develop Treatments for Patients with Rare Diseases

Congratulations to Jacob Hooker, the academic founder of Eikonizo Therapeutics, for entering a collaboration agreement with the McQuade Center for Strategic Research and Development, to develop inhibitors of histone deacetylase-6 (HDAC6) focused on treating amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s disease, and other diseases. 

The group is excited to have the resources needed to get a drug to patients in place and are hopeful that Eikonizo’s compounds can open up new treatment options for patients living with ALS and other rare diseases of high unmet need.